Irritable bowel syndrome (IBS) is a functional disorder of the intestine characterized by abdominal pain and altered bowel
habits. At present, no biological marker has been identified. Hence, the disease is clinically assessed on the basis of the
symptoms according to ROME IV criteria. Epidemiological data revealed that the prevalence of IBS varies widely around
the world, and more thorough research is needed to pinpoint any discrepancies that may exist between countries, as well
as possible reasons. Both pharmacological and non-pharmacological therapy is being used in order to treat IBS. There is
no specific treatment for irritable bowel disease that has come across the patients and only possible measures have been
taken to treat the severity of symptoms. Symptomatic treatment with spasmolytic agent like mebeverine has been considered
a standard therapy to relieve pain but to deal with constipation and diarrhea different treatment modalities have been adopted
by the physician